China Arrests 1300 People Suspected of Making and Selling Fake Medicines
Chinese police have rounded up more than 1300 people nationwide suspected of producing and selling fake medicine, state media have reported.
Authorities seized fake drugs and 9 tonnes of raw materials worth more than 2.2 billion yuan (£220 million), the state news agency Xinhua said, citing the ministry of public security.
It said police had shut down 140 illegal websites and online pharmacies in 29 provinces and major cities since June in the crackdown.
The seized fake drugs purported to deal with illnesses ranging from children's colds and flu to heart problems, and had been advertised online.
In July the cabinet's state food and drug administration announced a 6-month nationwide crackdown on the sale of illegal medicine, piling pressure on a sector already reeling from a bribery investigation at the British drugmaker GlaxoSmithKline.
Widespread counterfeit drugs and false advertising have been a thorn in the side of Chinese regulators for years, and the drug agency has conducted campaigns in the past to crack down.
Prosecutions for producing or selling fake drugs or toxic food jumped to more than 8000 in 2012, more than five times the number in 2011, according to a report by China's top prosecutor in March.
Beijing pledged to clean up the medicine sector following the deaths of at least 149 Americans who took contaminated Chinese supplies of the blood-thinner heparin in 2008.
But the country's complicated and still developing regulatory environment has stymied efforts at tackling the problem, which infuriates Chinese consumers, who also express anger at what they see as the high price of legitimate medicine.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance